The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

What this study is testing ClinicalTrials.gov NCT02501850 ↗

Description as written by the study sponsor.

Lipoprotein (a) \[Lp (a)\] is an independent cardiovascular risk (CVR) both in the general population and in patients with type 2 diabetes mellitus (DM-2). Until now no effective treatment is known to decrease the levels of Lp (a) levels and thus achieve a reduction of CVR. Among the new antidiabetic drugs are GLP-1Receptor agonists(GLP-1R). In addition to lowering blood glucose, these drugs have other beneficial effects. In our laboratory we have demonstrated that both native GLP-1 and various GLP-1R agonsits reduce the synthesis of Lp (a) in hepatocytes. The objective of the study is to test in humans the results observed in vitro. We will analyze whether treatment with GLP-1R agonists (Liraglutide, Exenatide or Lixisenatida) will reduce serum levels of Lp (a) in patients with DM-2.

Treatments tested

• Liraglutide also known as Exenatide, Lixisenatide Drug

  Treatment with liraglutide, exenatide or lixisenatide

• metformin also known as sulphonilurea Drug

  Treatment with metformin and/or sulphonilurea